Contribution of dipeptidyl peptidase 4 to non-typeable Haemophilus influenzae-induced lung inflammation in COPD

Sudhir Kotnala1, Yerin Kim1, Charu Rajput1

  • 1Department of Thoracic Surgery and Medicine, Temple University School of Medicine, Philadelphia, PA 16140, United States.

Insights

Enhanced dipeptidyl peptidase 4 (DPP4) expression in chronic obstructive pulmonary disease (COPD) lungs drives inflammation. DPP4 inhibition reduced lung inflammation in COPD mice infected with non-typeable Haemophilus influenzae (NTHi).

Area of Science:

  • Pulmonary immunology
  • Inflammatory diseases
  • Microbial pathogenesis

Background:

  • Dipeptidyl peptidase 4 (DPP4) expression is elevated in chronic obstructive pulmonary disease (COPD) lungs.
  • DPP4 is implicated in inflammation, including lipopolysaccharide-induced acute lung injury.
  • Non-typeable Haemophilus influenzae (NTHi) is a common cause of COPD exacerbations.

Purpose of the Study:

  • To investigate the role of DPP4 in NTHi-induced lung inflammation in COPD.
  • To evaluate the therapeutic potential of DPP4 inhibition in NTHi-infected COPD models.

Main Methods:

  • Pulmonary macrophages from COPD patients and healthy subjects were analyzed for DPP4 expression and inflammatory responses to NTHi.
  • A mouse model of COPD was infected with NTHi, and treated with a DPP4 inhibitor (diprotin A) or placebo.
  • Lung inflammation, DPP4 expression, and cytokine levels (IL-1β, CCL3) were assessed in both in vitro and in vivo models.

Main Results:

  • COPD macrophages exhibited higher baseline DPP4 expression and increased DPP4, IL-1β, and CCL3 responses to NTHi compared to normal macrophages.
  • DPP4 inhibition with diprotin A attenuated these inflammatory responses in COPD macrophages.
  • NTHi-infected COPD mice showed increased DPP4 expression, sustained neutrophilic lung inflammation, and elevated CCL3 levels, all of which were reduced by diprotin A treatment.

Conclusions:

  • Elevated DPP4 expression in pulmonary macrophages contributes to sustained lung inflammation in COPD following NTHi infection.
  • DPP4 inhibition represents a potential therapeutic strategy to mitigate the severity of NTHi-induced lung inflammation in COPD patients.